ella-ophelia-butler documents

NDA 21-399 ZD1839 for Treatment of NSCLC FDA Review Division of Oncology Drug Products
Documents NDA 21-399 ZD1839 for Treatment of NSCLC FDA Review Division of Oncology Drug Products